On 2 February 2009, the US Federal Trade Commission (FTC) announced that it filed a complaint in the US District Court for the Central District of California alleging that four drug companies violated US federal antitrust laws by providing and accepting monetary payments in exchange for delayed entry of generic versions of a branded medication, AndroGel. The complaint requests that the court enjoin the parties from enforcing these agreements and from engaging in similar conduct in the future.